Senior Research Associate
M.B.B.S. MPhil PhD PhD
Nasim Mavaddat is a Research Associate in cancer genetic epidemiology. She completed her MPhil in epidemiology and subsequently PhD in genetic epidemiology at the Department of Public Health and Primary Care, University of Cambridge. She also holds a PhD in molecular immunology. Her thesis was entitled gd T-cell function and antigen recognition and was conducted collaboratively between Stanford University and the University of Western Australia. She qualified in Medicine from U.W.A. and has carried out research in molecular Immunology at the Universities of Oxford and Cambridge.
Nasim’s research has focused on genetic susceptibility to breast cancer. She is presently investigating the value of genomic profiling for breast cancer risk stratification. The combined effect of multiple breast cancer susceptibility SNPs are represented in a polygenic risk score, which may be used for targeting breast cancer screening strategies, and risk reducing interventions to those at highest risk of developing breast cancer.
Nasim has also carried out work on risk modelling in BRCA1 and BRCA2 mutation carriers, studying tumour pathology in mutation carriers and estimating prospective breast cancer risks in BRCA1 and BRCA2 mutation carriers. Her PhD thesis involved incorporating tumour pathology information the genetic risk prediction algorithm BOADICEA. This work has now been used to extend the BOADICEA web interface, widely used by genetic counsellors and health practitioners for risk prediction.
Mavaddat N, Pharoah PD, Michailidou K et al (2015) Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst.107(5)
Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E et al. (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 105(11):812-22.
Mavaddat N, Barrowdale, D, Andrulis, I, Domchek, Eccles, D. et al. (2012) Pathology of breast, ovarian and contralateral breast cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 21(1):134-47.
Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M. (2010) Genetic susceptibility to breast cancer. Mol Oncol. 4, 174-191.
Mavaddat N, Rebbeck TR, Lakhani SR, Easton DF, Antoniou AC. (2010) Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res. 12, R28.